超快速MRI评估对导管原位癌组织学升级的预测价值
回顾性纳入53例活检证实的导管原位癌病灶,比较术后组织学未升级与升级为浸润癌两组的常规DCE-MRI及超快速MRI特征。病灶大小≥20 mm、最大斜率>11.5%/s、最大强化>229.1%为组织学升级的显著预测因素,三者联合可预测10例升级(10/17,58.8%)且无假阳性。
要点
- 病灶大小≥20 mm、最大斜率>11.5%/s、最大强化>229.1%为导管原位癌组织学升级的显著预测因素。
- 三项参数联合可预测10例组织学升级(10/17,58.8%)且无假阳性病例。
- 超快速MRI参数(最大斜率、最大强化)的观察者间一致性极好,组内相关系数分别为0.907和0.897。
关键影像表现/征象
- 升级组MRI病灶大小中位数40 mm(第25至75百分位数16.0-83.0)大于未升级组18.5 mm(10.0-29.8),p<0.001。
- 升级组最大斜率中位数12.1%/s(8.2-13.9)高于未升级组8.7%/s(6.4-11.1),p=0.004。
- 升级组最大强化中位数236.5%(153.7-253.7)高于未升级组175.4%(140.1-207.7),p=0.027。
诊断标准与关键数值
- 病灶大小≥20 mm、最大斜率>11.5%/s、最大强化>229.1%为组织学升级的显著预测因素。
- 三项参数联合可预测10例组织学升级(10/17,58.8%)且无假阳性病例。
- 超快速MRI参数观察者间一致性极好,最大斜率与最大强化的组内相关系数分别为0.907和0.897。
临床应用与阅片要点
- 术前超快速MRI联合常规DCE-MRI可能有助于导管原位癌患者的治疗决策。
- 病灶大小≥20 mm、最大斜率>11.5%/s、最大强化>229.1%提示组织学升级可能,联合应用可预测部分升级病例且无假阳性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The purpose of this study was to investigate the usefulness of ultrafast MRI with conventional dynamic contrast-enhanced (DCE)-MRI for predicting histologic upgrade of ductal carcinoma in situ (DCIS) to invasive cancer.
METHODS: This retrospective study enrolled 53 biopsy-proven DCIS lesions in 53 patients and divided into two groups based on postoperative histopathologic diagnoses: non-upgrade and upgrade to invasive cancer groups. Imaging features of conventional DCE-MRI and ultrafast MRI, and histopathologic features were reviewed and compared between the two groups. Interobserver agreements for MRI features were analyzed by two radiologists. The radiologic and histopathologic parameters for predicting histologic upgrade of DCIS were identified using multiple linear regression.
RESULTS: Seventeen lesions (32.1 %) were histologically upgraded to invasive cancer after surgery. The interobserver agreement for ultrafast MRI parameters was excellent, and maximum slope (MS) and maximum enhancement (ME) showed the highest reliability (intraclass correlation coefficients, 0.907 and 0.897, respectively). The upgrade group showed significantly larger lesion size on MRI (median 40 mm [25th to 75th percentiles 16.0-83.0] vs. 18.5 mm [10.0-29.8], p < 0.001), higher MS (12.1 %/s [8.2-13.9] vs. 8.7 %/s [6.4-11.1], p = 0.004), and higher ME (236.5 % [153.7-253.7] vs. 175.4 % [140.1-207.7], p = 0.027) than non-upgrade group. Lesion size (≥ 20 mm), MS (> 11.5 %), and ME (> 229.1 %) were significant predictors for histologic upgrade, which could predict 10 cases of histologic upgrade (10/17, 58.8 %) without a false-positive case.
CONCLUSION: Preoperative ultrafast MRI with conventional DCE-MRI could be useful in management decisions for DCIS patients.
引用
- Heo S, Park AY, Jung HK, et al. The usefulness of ultrafast MRI evaluation for predicting histologic upgrade of ductal carcinoma in situ. Eur J Radiol. 2021. PMID: 33429208. doi:10.1016/j.ejrad.2020.109519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。